Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF MAY 25, 2022 SAM #7481
SPECIAL NOTICE

65 -- Lutathera & Pluvicto

Notice Date

5/23/2022 8:31:19 AM
 

Notice Type

Special Notice
 

NAICS

325412 — Pharmaceutical Preparation Manufacturing
 

Contracting Office

W40M USA HLTH CONTRACTING ACT JBSA FT SAM HOUSTON TX 78234-0000 USA
 

ZIP Code

78234-0000
 

Solicitation Number

W81K0022Q0097
 

Response Due

5/30/2022 8:00:00 AM
 

Point of Contact

Cathy Harris, Phone: 2102213245
 

E-Mail Address

cathy.l.harris2.civ@mail.mil
(cathy.l.harris2.civ@mail.mil)
 

Description

The Regional Health Contracting Office-Central, JBSA - Fort Sam Houston, Texas intends to award a Firm-Fixed-Price sole source contract to Advance Accelerator Applications USA, Inc. under the authority of Federal Acquisition Regulation (FAR) 13.501(a)(1)(ii), sole source, for the requirement for two FDA approved products LUTATHERA (lutetium Lu 177 dotatate) and PLUVICTO (lutetium Lu 177 vipivotide tetraxetan). Lutathera is indicated for the imaging and treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors for patients. Pluvicto is for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration resistant prostate cancer. � The applicable NAICS code for this requirement is 325412, Pharmaceutical Preparation Manufacturing. The Small Business Size Standard is 1,250 employees.� Award will be made on or after 1 Aug 2022. The solicitation number is W81K0022Q0097, and is generated for the purposes of posting this notice. THIS NOTICE OF INTENT IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. A determination by the Government not to compete the purchase order based upon responses to this notice is solely within the discretion of the Government. This notice is neither a request for quotes nor a solicitation of offers; however, interested sources who submit data are responsible for appropriately marking information if it is proprietary in nature. Questions will not be accepted after the due date. All responses must be received by 30 May 2022-10:00AM CST Salient Characteristics: Lutetium Lu-177 Dotatate (LUTATHERA) Must be FDA approved. Must be Lu-177 Dotatate Must be indicated for treatment of somatostatin receptor-positive gastroenterpancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors. Should be a 4 dose treatment regimen given every 8 weeks. Lutetium Lu-177 Vipivotide Tetraxetan (PLUVICTO) Must be FDA approved Must be Lu-177 Vipivotide Tetraxetan Must be indicated for treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Should be a treatment regimen of every 6 weeks for up to 6 doses. Contracting Office Address: Regional Healthcare Contracting Office- Central Attn: MCAA-RC, 3551 Roger Brooke Drive JBSA-Fort Sam Houston, TX 78234-6200
 

Web Link

SAM.gov Permalink
(https://sam.gov/opp/715201fb84904fbd97a9202a4d489627/view)
 

Place of Performance

Address: JBSA Ft Sam Houston, TX 78234, USA

Zip Code: 78234

Country: USA
 

Record

SN06334769-F 20220525/220523230057 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |